Grant: CIHR Fellowship
Direct Payment
$100,000.00
Prostacyclin-PTGIR Signaling in T Cell Exhaustion: Unlocking New Avenues for Boosting Anti-Cancer Immunity
FY 2023-24
Summary
Our body has immune cells called CD8 T cells that multiply and release substances that kill cancer cells. But, when these cells are exposed to cancer for a long time, they become tired and don't work well. This is known as "T cell exhaustion" and is a big hurdle in treating cancer.
Some treatments, called Immune checkpoint inhibitors (ICIs), help patients by blocking T cell exhaustion. But for many patients, these treatments are not effective.
My objective is to find new ways to stop T cell exhaustion in order to improve patient survival.
I looked at genetic info from exhausted T (Tex) cells in tumors and found that a gene called PTGIR-which makes a receptor for prostacyclin (a fat)-is very active in Tex cells, but absent in high-functioning CD8 T cells. Also, I found that patients whose cancer cells produce a lot of prostacyclin, have poor survival outcomes.
I believe the interaction between prostacyclin and PTGIR drives a program that makes T cells tired. If I block this interaction, I may be able to make tired T cells function better. To test this theory I have 2 aims:
1.Define how PTGIR expression in T cells affects their ability to control cancer. If PTGIR is absent in high-functioning T cells, what happens if I remove PTGIR in exhausted T cells? Here I will use genetics to delete PTGIR in T cells, transfer these cells into mice that have tumors and assess the T cell's capacity to multiply, and release substances that kill cancer cells.
2.Define how prostacyclin in tumors affects T cell function and tumor growth. If high prostacyclin in cancer is associated with high death rates in patients, what happens if I stop cancer cells from making prostacyclin? I will do this by using genetics to modify cancer cells and then test how this affects T cell function and tumor growth in mice.
This research aims to define how the PTGIR-prostacyclin connection leads to T cell exhaustion in cancer and whether it can be targeted to make cancer treatment more effective.
Department
Program
CIHR Fellowship
Recipient
Location
Michigan, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
492972
Name
Dahabieh Michael
Region
Michigan
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Prostacyclin-PTGIR Signaling in T Cell Exhaustion: Unlocking New Avenues for Boosting Anti-Cancer Immunity
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Cancer Cell Metabolism; Cd8 T Cell Exhaustion; Immune Checkpoint Blockade; Immunotherapy; Metabolomics; Prostacyclin; Prostacyclin Receptor
Abstract
Our body has immune cells called CD8 T cells that multiply and release substances that kill cancer cells. But, when these cells are exposed to cancer for a long time, they become tired and don't work well. This is known as "T cell exhaustion" and is a big hurdle in treating cancer.
Some treatments, called Immune checkpoint inhibitors (ICIs), help patients by blocking T cell exhaustion. But for many patients, these treatments are not effective.
My objective is to find new ways to stop T cell exhaustion in order to improve patient survival.
I looked at genetic info from exhausted T (Tex) cells in tumors and found that a gene called PTGIR-which makes a receptor for prostacyclin (a fat)-is very active in Tex cells, but absent in high-functioning CD8 T cells. Also, I found that patients whose cancer cells produce a lot of prostacyclin, have poor survival outcomes.
I believe the interaction between prostacyclin and PTGIR drives a program that makes T cells tired. If I block this interaction, I may be able to make tired T cells function better. To test this theory I have 2 aims:
1.Define how PTGIR expression in T cells affects their ability to control cancer. If PTGIR is absent in high-functioning T cells, what happens if I remove PTGIR in exhausted T cells? Here I will use genetics to delete PTGIR in T cells, transfer these cells into mice that have tumors and assess the T cell's capacity to multiply, and release substances that kill cancer cells.
2.Define how prostacyclin in tumors affects T cell function and tumor growth. If high prostacyclin in cancer is associated with high death rates in patients, what happens if I stop cancer cells from making prostacyclin? I will do this by using genetics to modify cancer cells and then test how this affects T cell function and tumor growth in mice.
This research aims to define how the PTGIR-prostacyclin connection leads to T cell exhaustion in cancer and whether it can be targeted to make cancer treatment more effective.
Competitiondate
202310
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Dahabieh, Michael
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $100,000~ $0~